Instil Bio Inc (TIL)

May 30, 2025, 7:00 AM EDT - 1 day ago

Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference

May 25, 2025, 7:09 AM EDT - 6 days ago

Instil Bio: Second-Half 2025 AXN-2510 Data Could Mark Another PD-1/VEGF Success

May 23, 2025, 7:00 AM EDT - 8 days ago

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

May 22, 2025, 6:00 AM EDT - 9 days ago

Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025

May 13, 2025, 7:00 AM EDT - 18 days ago

Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 4, 2025, 7:09 AM EST - 3 months ago

Instil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Jan 14, 2025, 7:00 AM EST - 4 months ago

Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody

Jan 7, 2025, 2:06 PM EST - 5 months ago

Bullish Outlook On Instil Bio's Investigational Cancer Drug: Jefferies Sees Over 300% Stock Upside

Dec 1, 2024, 5:00 AM EST - 6 months ago

Instil Bio's Strategic Shift To SYN-2510: A Speculative 'Buy' Opportunity

Sep 16, 2024, 12:31 PM EDT - 9 months ago

Crude Oil Surges Over 1%; Instil Bio Shares Plunge

Sep 16, 2024, 6:00 AM EDT - 9 months ago

Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer

Sep 13, 2024, 1:22 PM EDT - 9 months ago

Instil Bio: PD-L1/VEGF Bispecific Targeting With Unique Enhancements

Aug 13, 2024, 5:00 PM EDT - 10 months ago

Instil Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 1, 2024, 6:00 AM EDT - 10 months ago

Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody

May 10, 2024, 7:00 AM EDT - 1 year ago

Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update

Mar 21, 2024, 5:00 PM EDT - 1 year ago

Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Jan 16, 2024, 8:00 AM EST - 1 year ago

Instil Bio Announces Strategic Update

Dec 5, 2023, 5:00 PM EST - 1 year ago

Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split

Nov 13, 2023, 5:00 PM EST - 1 year ago

Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 6, 2023, 7:00 AM EST - 1 year ago

Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting

Aug 14, 2023, 7:00 AM EDT - 1 year ago

Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 26, 2023, 4:38 PM EDT - 2 years ago

Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference

May 11, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

Mar 31, 2023, 7:00 AM EDT - 2 years ago

Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Jan 31, 2023, 5:00 PM EST - 2 years ago

Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site

Jan 18, 2023, 1:58 PM EST - 2 years ago

7 Cheap But Risky Biotech Stocks

BCAB IMRX NKTX

Jan 9, 2023, 7:00 AM EST - 2 years ago

Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer

Dec 12, 2022, 11:45 AM EST - 2 years ago

Newman Ferrara LLP Announces Corporate Governance Investigations of Instil Bio, Inc. (TIL)

Dec 8, 2022, 7:00 AM EST - 2 years ago

Instil Bio Announces Prioritization of Genetically Engineered CoStAR-TIL Program with ITIL-306 in Advanced Solid Tumors and Reduction in Workforce

Nov 14, 2022, 4:07 PM EST - 2 years ago

Instil Bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 6:13 PM EST - 2 years ago

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 8, 2022, 7:00 AM EST - 2 years ago

Instil Bio Announces Poster Presentations of CoStAR Platform at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 7, 2022, 8:59 AM EST - 2 years ago

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 2, 2022, 9:39 AM EDT - 2 years ago

INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Nov 1, 2022, 5:30 PM EDT - 2 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 1:33 PM EDT - 2 years ago

The Law Offices of Frank R. Cruz Announces Investigation of Instil Bio, Inc. (TIL) on Behalf of Investors

Nov 1, 2022, 10:50 AM EDT - 2 years ago

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Instil Bio, Inc. with Losses of $100,000 to Contact the Firm

Oct 31, 2022, 8:52 AM EDT - 2 years ago

Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials

Oct 31, 2022, 7:00 AM EDT - 2 years ago

Instil Bio Announces Voluntary Pause of Enrollment in Ongoing Clinical Trials Related to Manufacturing

Oct 18, 2022, 7:00 AM EDT - 2 years ago

Instil Bio Announces First Patient Dosed with ITIL-306, our First Engineered TIL Therapy Using the CoStAR Platform Targeting Folate Receptor Alpha (FRα), in Non-Small Cell Lung Cancer

Sep 19, 2022, 7:20 AM EDT - 2 years ago

Instil Bio to Present at Jefferies Cell and Genetic Medicine Summit

Sep 9, 2022, 7:00 AM EDT - 2 years ago

Instil Bio to Present at Morgan Stanley Global Healthcare Conference

Sep 6, 2022, 7:00 AM EDT - 2 years ago

Instil Bio Announces Appointment of Tim Moore as Chief Operating Officer